HEREDITARY ANGIOEDEMA MARKET ANALYSIS

Hereditary Angioedema Market is segmented By Type (Hereditary Angioedema Type I and Hereditary Angioedema Type II), By Drug Class (C1 Esterase Inhibitor, Kallikrein Inhibitor, Bradykinin Receptor, Attenuated Androgens, and Others), By Route of Administration (Subcutaneous, Intravenous, and Oral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

Published In : Feb 2025
Code : CMI1292
Pages :175
Formats :
Excel and PDF
Industry : Pharmaceutical

Hereditary Angioedema Market Size and Trends

Hereditary angioedema market is estimated to be valued at USD 3.13 Bn in 2025 and is expected to reach USD 5.96 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 9.6% from 2025 to 2032.

Hereditary Angioedema Market Key Factors

To learn more about this report, Request sample copy

The hereditary angioedema market growth is primarily driven by increasing awareness of the condition and the availability of novel treatment options. Enhanced diagnostic technologies have led to more accurate and earlier diagnoses, expanding the patient base and boosting demand for effective therapies. The introduction of oral medications allows for convenient self-administration at home, making them preferable to traditional injectable treatments. However, the market faces significant restraints, particularly the high costs associated with these medications, which can limit accessibility for many patients.